Published in J Transl Med on March 24, 2010
Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol (1999) 40.46
Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med (2003) 31.67
Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. Proc Natl Acad Sci U S A (1992) 7.72
Efficient intracellular assembly of papillomaviral vectors. J Virol (2004) 5.36
The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years. J Infect Dis (2009) 5.09
Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas. Proc Natl Acad Sci U S A (1995) 4.15
Immunization with viruslike particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection. J Virol (1995) 4.14
In vitro generation and type-specific neutralization of a human papillomavirus type 16 virion pseudotype. J Virol (1996) 3.66
Generation of HPV pseudovirions using transfection and their use in neutralization assays. Methods Mol Med (2005) 3.26
Structural polypeptides of rabbit, bovine, and human papillomaviruses. J Virol (1975) 2.83
Effective vaccination against papilloma development by immunization with L1 or L2 structural protein of cottontail rabbit papillomavirus. Virology (1992) 2.53
Neutralization of bovine papillomavirus by antibodies to L1 and L2 capsid proteins. J Virol (1994) 2.52
Arrangement of L2 within the papillomavirus capsid. J Virol (2008) 2.37
Minor capsid protein of human genital papillomaviruses contains subdominant, cross-neutralizing epitopes. Virology (2000) 2.25
The open reading frame L2 of cottontail rabbit papillomavirus contains antibody-inducing neutralizing epitopes. Virology (1991) 2.24
Protection against heterologous human papillomavirus challenge by a synthetic lipopeptide vaccine containing a broadly cross-neutralizing epitope of L2. Proc Natl Acad Sci U S A (2008) 2.00
Mutagenesis of a flexible loop in streptavidin leads to higher affinity for the Strep-tag II peptide and improved performance in recombinant protein purification. Protein Eng (1997) 1.85
Human papillomavirus types 6 and 11 have antigenically distinct strongly immunogenic conformationally dependent neutralizing epitopes. Virology (1994) 1.64
Protective immunity to rabbit oral and cutaneous papillomaviruses by immunization with short peptides of L2, the minor capsid protein. J Virol (2002) 1.48
Vaccination of cattle with the N-terminus of L2 is necessary and sufficient for preventing infection by bovine papillomavirus-4. Virology (1995) 1.48
In vitro gene transfer using human papillomavirus-like particles. Nucleic Acids Res (1998) 1.44
Immunological analyses of human papillomavirus capsids. Vaccine (2001) 1.40
Kinetics of in vitro adsorption and entry of papillomavirus virions. Virology (2004) 1.37
Identification of two cross-neutralizing linear epitopes within the L1 major capsid protein of human papillomaviruses. J Virol (2002) 1.35
Chimeric L1-L2 virus-like particles as potential broad-spectrum human papillomavirus vaccines. J Virol (2009) 1.35
L1 interaction domains of papillomavirus l2 necessary for viral genome encapsidation. J Virol (2001) 1.34
Vaccination of cattle with bovine papillomavirus type 4 L2 elicits the production of virus-neutralizing antibodies. J Gen Virol (1996) 1.32
Vaccination of healthy volunteers with human papillomavirus type 16 L2E7E6 fusion protein induces serum antibody that neutralizes across papillomavirus species. Cancer Res (2006) 1.26
The L1 major capsid protein of human papillomavirus type 16 variants affects yield of virus-like particles produced in an insect cell expression system. J Clin Microbiol (1998) 1.25
A peptide encoding a B-cell epitope from the N-terminus of the capsid protein L2 of bovine papillomavirus-4 prevents disease. Virology (1997) 1.22
In vitro infection and type-restricted antibody-mediated neutralization of authentic human papillomavirus type 16. J Virol (1998) 1.20
Gene transfer using human papillomavirus pseudovirions varies according to virus genotype and requires cell surface heparan sulfate. FEMS Microbiol Lett (2001) 1.19
Dissection of human papillomavirus type 33 L2 domains involved in nuclear domains (ND) 10 homing and reorganization. Virology (2003) 1.14
Human papillomavirus type 45 propagation, infection, and neutralization. Virology (2003) 1.09
Vaccination with HPV16 L2E6E7 fusion protein in GPI-0100 adjuvant elicits protective humoral and cell-mediated immunity. Vaccine (2008) 1.05
Papillomavirus pseudovirus: a novel vaccine to induce mucosal and systemic cytotoxic T-lymphocyte responses. J Virol (2001) 1.03
Identification of type-specific and cross-reactive neutralizing conformational epitopes on the major capsid protein of human papillomavirus type 31. Arch Virol (2006) 1.02
Detection of human papillomavirus type 31-neutralizing antibodies from naturally infected patients by an assay based on intracellular assembly of luciferase-expressing pseudovirions. Clin Vaccine Immunol (2007) 0.88
Inhibition of cervical cancer cell growth by human papillomavirus virus-like particles packaged with human papillomavirus oncoprotein short hairpin RNAs. Mol Cancer Ther (2009) 0.86
Prophylactic DNA immunization against multiple papillomavirus types. Vaccine (2007) 0.83
Induction of antibody response against hepatitis E virus (HEV) with recombinant human papillomavirus pseudoviruses expressing truncated HEV capsid proteins in mice. Vaccine (2008) 0.79
Prophylactic human papillomavirus vaccines: potential for sea change. Expert Rev Vaccines (2007) 0.78
Genetic diversity of hepatitis B virus strains derived worldwide: genotypes, subgenotypes, and HBsAg subtypes. Intervirology (2004) 4.12
Human papillomavirus types 16, 31, and 58 use different endocytosis pathways to enter cells. J Virol (2003) 1.79
Risk factors of invasive cervical cancer in Mali. Int J Epidemiol (2002) 1.74
Prevalence of human papillomavirus infection in women in Busan, South Korea. Int J Cancer (2003) 1.71
Pulmonary bacteriophage therapy on Pseudomonas aeruginosa cystic fibrosis strains: first steps towards treatment and prevention. PLoS One (2011) 1.63
High levels of antibodies against merkel cell polyomavirus identify a subset of patients with merkel cell carcinoma with better clinical outcome. J Clin Oncol (2011) 1.53
Population-based human papillomavirus prevalence in Lampang and Songkla, Thailand. J Infect Dis (2003) 1.47
Generation of Merkel cell polyomavirus (MCV)-like particles and their application to detection of MCV antibodies. J Clin Microbiol (2010) 1.40
Age-specific seroprevalences of merkel cell polyomavirus, human polyomaviruses 6, 7, and 9, and trichodysplasia spinulosa-associated polyomavirus. Clin Vaccine Immunol (2013) 1.36
Identification of two cross-neutralizing linear epitopes within the L1 major capsid protein of human papillomaviruses. J Virol (2002) 1.35
Clinician's guide to human papillomavirus immunology: knowns and unknowns. Lancet Infect Dis (2009) 1.29
Cervical cancer control, priorities and new directions. Int J Cancer (2004) 1.23
Chapter 15: HPV vaccine use in the developing world. Vaccine (2006) 1.23
Serologic response to human oncogenic papillomavirus types 16, 18, 31, 33, 39, 58 and 59 virus-like particles in colombian women with invasive cervical cancer. Int J Cancer (2002) 1.21
Seroprevalence of antibodies against human papillomavirus (HPV) types 16 and 18 in four continents: the International Agency for Research on Cancer HPV Prevalence Surveys. Cancer Epidemiol Biomarkers Prev (2010) 1.16
Merkel cell polyomavirus infection occurs during early childhood and is transmitted between siblings. J Clin Virol (2013) 1.06
Merkel cell polyomavirus strains in patients with merkel cell carcinoma. Emerg Infect Dis (2009) 1.05
Neutrophil elastase degrades cystic fibrosis transmembrane conductance regulator via calpains and disables channel function in vitro and in vivo. Am J Respir Crit Care Med (2012) 1.03
Seroprevalence and cross-reactivity of human polyomavirus 9. Emerg Infect Dis (2012) 1.00
Hepatitis E virus seroprevalence and risk factors for individuals in working contact with animals. J Clin Virol (2013) 0.96
Human papillomavirus L1 protein expressed in tobacco chloroplasts self-assembles into virus-like particles that are highly immunogenic. Plant Biotechnol J (2008) 0.96
High hepatitis E virus seroprevalence in forestry workers and in wild boars in France. J Clin Microbiol (2012) 0.95
Positively charged sequences of human papillomavirus type 16 capsid proteins are sufficient to mediate gene transfer into target cells via the heparan sulfate receptor. J Gen Virol (2003) 0.91
BK virus and cancer in Uganda. Eur J Cancer Prev (2006) 0.91
Detection of neutralizing antibodies against human papillomaviruses (HPV) by inhibition of gene transfer mediated by HPV pseudovirions. J Clin Microbiol (2002) 0.91
TFPI-2 silencing increases tumour progression and promotes metalloproteinase 1 and 3 induction through tumour-stromal cell interactions. J Cell Mol Med (2011) 0.90
Disruption of cytokeratin-8 interaction with F508del-CFTR corrects its functional defect. Hum Mol Genet (2011) 0.89
Investigation of the prevalence of antibodies against neurotropic polyomaviruses BK, JC and SV40 in sera from patients affected by multiple sclerosis. Neurol Sci (2010) 0.88
Detection of human papillomavirus type 31-neutralizing antibodies from naturally infected patients by an assay based on intracellular assembly of luciferase-expressing pseudovirions. Clin Vaccine Immunol (2007) 0.88
Seroprevalence of human Malawi polyomavirus. J Clin Microbiol (2013) 0.87
Inhibition of cervical cancer cell growth by human papillomavirus virus-like particles packaged with human papillomavirus oncoprotein short hairpin RNAs. Mol Cancer Ther (2009) 0.86
Identification of neutralizing conformational epitopes on the human papillomavirus type 31 major capsid protein and functional implications. Protein Sci (2009) 0.86
Mutations on the FG surface loop of human papillomavirus type 16 major capsid protein affect recognition by both type-specific neutralizing antibodies and cross-reactive antibodies. J Med Virol (2005) 0.84
Molecular epidemiology of merkel cell polyomavirus: evidence for geographically related variant genotypes. J Clin Microbiol (2014) 0.83
Use of interferon-alpha in two patients with Merkel cell carcinoma positive for Merkel cell polyomavirus. Acta Oncol (2010) 0.83
Natural killer and dendritic cells collaborate in the immune response induced by the vaccine against uterine cervical cancer. Eur J Immunol (2014) 0.82
Human Merkel cell polyomavirus: virological background and clinical implications. APMIS (2013) 0.81
Positively charged synthetic peptides from structural proteins of papillomaviruses abrogate human papillomavirus infectivity. J Med Virol (2004) 0.80
Induction of antibody response against hepatitis E virus (HEV) with recombinant human papillomavirus pseudoviruses expressing truncated HEV capsid proteins in mice. Vaccine (2008) 0.79
Human papillomavirus type 16 pseudovirions with few point mutations in L1 major capsid protein FG loop could escape actual or future vaccination for potential use in gene therapy. Mol Biotechnol (2014) 0.77
Anti-HPV16 E2 protein T-cell responses and viral control in women with usual vulvar intraepithelial neoplasia and their healthy partners. PLoS One (2012) 0.76
Multilevel control of glucose homeostasis by adenylyl cyclase 8. Diabetologia (2014) 0.76
Guiding pancreatic beta cells to target electrodes in a whole-cell biosensor for diabetes. Lab Chip (2015) 0.75
[Vaccination against human papillomavirus infections]. Rev Prat (2006) 0.75
[HPV immunization for the prevention of cervical cancer]. Presse Med (2009) 0.75
Somatostatin Receptors 2A and 5 Are Expressed in Merkel Cell Carcinoma with No Association with Disease Severity. Neuroendocrinology (2015) 0.75
[Merkel cell carcinoma: a virus-induced tumor?]. Presse Med (2008) 0.75
Recurrent primary cutaneous mucinous carcinoma with neuroendocrine differentiation: case report and review of the literature. J Cutan Pathol (2014) 0.75